
Xuqing Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1914716/publications.pdf Version: 2024-02-01



Χυρικς Ζηλής

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Design, Synthesis, and in Vivo SAR of a Novel Series of Pyrazolines as Potent Selective Androgen Receptor Modulators. Journal of Medicinal Chemistry, 2007, 50, 3857-3869. | 6.4 | 80 |
| 2 | Deciphering the selective androgen receptor modulators paradigm. Expert Opinion on Drug Discovery, 2013, 8, 191-218. | 5.0 | 53 |
| 3 | Electron Density Guided Fragment-Based Lead Discovery of Ketohexokinase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 7979-7991. | 6.4 | 33 |
| 4 | A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats. Endocrine, 2007, 32, 41-51. | 2.2 | 30 |
| 5 | Synthesis and SAR of novel hydantoin derivatives as selective androgen receptor modulators. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5763-5766. | 2.2 | 29 |
| 6 | Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3233-3237. | 2.2 | 26 |
| 7 | Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgen receptor modulators. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 439-443. | 2.2 | 24 |
| 8 | Optimization of a pyrazole hit from FBDD into a novel series of indazoles as ketohexokinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4762-4767. | 2.2 | 22 |
| 9 | Recent advances in the development of selective androgen receptor modulators. Expert Opinion on Therapeutic Patents, 2009, 19, 1239-1258. | 5.0 | 20 |
| 10 | Design, synthesis and SAR of a novel series of heterocyclic phenylpropanoic acids as GPR120 agonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3272-3278. | 2.2 | 20 |
| 11 | Targeting Enteropeptidase with Reversible Covalent Inhibitors To Achieve Metabolic Benefits. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 510-521. | 2.5 | 19 |
| 12 | Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes. ACS Medicinal Chemistry Letters, 2017, 8, 947-952. | 2.8 | 17 |
| 13 | Evaluation of anti-diabetic effect and gall bladder function with 2-thio-5-thiomethyl substituted imidazoles as TGR5 receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1760-1764. | 2.2 | 16 |
| 14 | GPR120 agonists for the treatment of diabetes: a patent review (2014 present). Expert Opinion on Therapeutic Patents, 2020, 30, 729-742. | 5.0 | 16 |
| 15 | β-Alkylthio indolyl carbinols: Potent nonsteroidal antiandrogens with oral efficacy in a prostate cancer model. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2545-2548. | 2.2 | 11 |
| 16 | Discovery of Orally Efficacious Tetrahydrobenzimidazoles as TGR5 Agonists for Type 2 Diabetes. ACS Medicinal Chemistry Letters, 2017, 8, 560-565. | 2.8 | 8 |
| 17 | Pharmacological characterization of an imidazolopyrazole as novel selective androgen receptor modulator. Journal of Steroid Biochemistry and Molecular Biology, 2013, 134, 51-58. | 2.5 | 5 |
| 18 | Discovery of a Novel Series of Pyridone-Based EP3 Antagonists for the Treatment of Type 2 Diabetes. ACS Medicinal Chemistry Letters, 2021, 12, 451-458. | 2.8 | 3 |

XUQING ZHANG

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Optimization of physicochemical properties of pyridone-based EP3 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2021, 47, 128172. | 2.2 | 3 |
| 20 | Discovery of a novel series of guanidinebenzoates as gut-restricted enteropeptidase and trypsin dual inhibitors for the treatment of metabolic syndrome. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 127939. | 2.2 | 2 |
| 21 | Therapeutic Potential of EP3 Receptor Antagonists for Treatment of Noninsulin Dependent Diabetes Mellitus across Multiple Preclinical Models. Diabetes, 2018, 67, 250-LB. | 0.6 | 2 |
| 22 | Discovery and Optimization of 7-Alkylidenyltetrahydroindazole-Based Acylsulfonamide EP3 Antagonists. ACS Medicinal Chemistry Letters, 2022, 13, 111-117. | 2.8 | 0 |